Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
PF-3512676 dosing was stopped 20 June 2007 in response to DSMC recommendation to close the trial, citing lack of efficacy concerns as the primary reason with a safety issue (sepsis) also contributing to the decision. Subjects were allowed to complete standard of care treatment/survival follow-up. Data collection was completed on 17 July 2008.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Advanced Non-Small-Cell Lung Cancer (NSCLC) stage IIIB with pleural effusion or stage IV
No prior systemic treatment for Non-Small-Cell Lung Cancer (NSCLC)with chemotherapy, immunotherapy, biologic response modifiers or other investigational drugs
Eastern Cooperative Oncology Performance Status (ECOG PS) 0 or 1
You may not be if
Small cell or carcinoid lung cancer
Known Central Nervous System (CNS) metastasis
Pre-existing auto-immune or antibody mediated diseases
Clareo Health | Trial of Paclitaxel/Carboplatin + PF-3512676 vs Paclitaxel/Carboplatin Alone in Patients With Advanced Non-Small Cell Lung Cancer
